WO1996004368A1 - Propagation et differenciation inductible de cellules souches du systeme nerveux central f×tal humain - Google Patents
Propagation et differenciation inductible de cellules souches du systeme nerveux central f×tal humain Download PDFInfo
- Publication number
- WO1996004368A1 WO1996004368A1 PCT/CA1995/000445 CA9500445W WO9604368A1 WO 1996004368 A1 WO1996004368 A1 WO 1996004368A1 CA 9500445 W CA9500445 W CA 9500445W WO 9604368 A1 WO9604368 A1 WO 9604368A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- nervous system
- central nervous
- cell
- differentiated
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 82
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 65
- 230000001605 fetal effect Effects 0.000 title claims abstract description 53
- 230000004069 differentiation Effects 0.000 title claims description 36
- 230000001939 inductive effect Effects 0.000 title claims description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 244
- 238000000034 method Methods 0.000 claims abstract description 55
- 230000008569 process Effects 0.000 claims abstract description 40
- 210000002966 serum Anatomy 0.000 claims abstract description 28
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 27
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 25
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 25
- 230000002062 proliferating effect Effects 0.000 claims abstract description 18
- 238000012258 culturing Methods 0.000 claims abstract description 17
- 238000007423 screening assay Methods 0.000 claims abstract description 13
- 238000004115 adherent culture Methods 0.000 claims abstract description 12
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 5
- 239000000126 substance Substances 0.000 claims description 49
- 239000002609 medium Substances 0.000 claims description 46
- 230000035755 proliferation Effects 0.000 claims description 40
- 210000002569 neuron Anatomy 0.000 claims description 38
- 239000001963 growth medium Substances 0.000 claims description 37
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 26
- 230000001413 cellular effect Effects 0.000 claims description 22
- 210000004498 neuroglial cell Anatomy 0.000 claims description 17
- 210000004556 brain Anatomy 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 102000013275 Somatomedins Human genes 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 241000283073 Equus caballus Species 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 238000007747 plating Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 abstract description 11
- 210000001519 tissue Anatomy 0.000 description 34
- 102400001368 Epidermal growth factor Human genes 0.000 description 20
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 210000004129 prosencephalon Anatomy 0.000 description 14
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000001537 neural effect Effects 0.000 description 12
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 7
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 7
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 7
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 7
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 210000001938 protoplast Anatomy 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000002518 glial effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000005700 Putrescine Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000001259 mesencephalon Anatomy 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 3
- 108010088373 Neurofilament Proteins Proteins 0.000 description 3
- 102000008763 Neurofilament Proteins Human genes 0.000 description 3
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 102400000096 Substance P Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000000768 catecholaminergic effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 210000003618 cortical neuron Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 210000005044 neurofilament Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical class [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000017047 asymmetric cell division Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 210000003737 chromaffin cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000003619 fibrillary effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 2
- 210000001362 glutamatergic neuron Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- -1 neural transmitters Proteins 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 210000002951 peptidergic neuron Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011536 re-plating Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZMKBTZQKANQZSK-UHFFFAOYSA-N 2-(methylamino)-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid Chemical compound CNC(C(O)=O)CC1=C(C)ON=C1O ZMKBTZQKANQZSK-UHFFFAOYSA-N 0.000 description 1
- USNYHYIHBMWMND-UHFFFAOYSA-N 2-amino-3-(3-hydroxy-5-methyl-2h-1,2-oxazol-3-yl)propanoic acid Chemical compound CC1=CC(O)(CC(N)C(O)=O)NO1 USNYHYIHBMWMND-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000700167 Mastomys natalensis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241001486234 Sciota Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 239000000928 excitatory amino acid agonist Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000052073 human NGFR Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 108010091047 neurofilament protein H Proteins 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002263 peptidergic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000003863 superior colliculi Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
Definitions
- the present invention relates to processes and compositions for preparing human fetal central nervous system progenitor cells and differentiated neuronal and glial cells; as well as their use.
- the mammalian central nervous system originates from cells of the embryonic neural tube. During development, these cells proliferate and differentiate into the diverse cell types of the mature central nervous system (CNS), including neurons and glia. Multipotential proliferating cells derived from fetal rat striatum, fetal rat cerebral cortex, post natal rat forebrain, chicken optic tectum and foetal and adult mouse striatum have been propagated in vitro and found capable of generating neurons and glia; long- term propagation of similar progenitor cells of human origin has not yet been described.
- CNS central nervous system
- epidermal growth factor exerts a mitogenic action on low-density, dissociated cultures of adult and fetal mouse CNS tissue, yielding mixed cultures of neurons and astrocytes presumably arising from a population of multipotent progenitor cells (See
- EGF EGF-like growth factors
- IGF-I and IGF-II Insulin-like growth factors
- IGF-I insulin-like growth factors
- the present invention provides that epidermal growth factor, when added to a partially defined medium, allows the survival and proliferation of progenitor cells from human forebrain, including primordia of the cortex, striatum and basal forebrain.
- progenitors can be maintained in a proliferating state for months. At any time, they can be induced to differentiate into neurochemically defined neuron and glia consistent with the cell types found in these forebrain areas in the mature state. Differentiated neurons derived from the progenitor cells display ligand-gated conductances characteristic of normal mammalian neurons.
- the present invention provides a process of preparing a human fetal central nervous system progenitor cell comprising the steps of:
- the central nervous system tissue can be from the spinal cord or the brain.
- Brain tissue can be from any specific region of the brain as exemplified by ventral forebrain tissue, cerebral cortex tissue or tissue from midbrain precursor.
- the effective amount of epidermal growth factor is from about 1 ng/ml to about 100 ng/ml of culture medium, more preferably from about 10 to about 50 ng/ml of culture medium and, even more preferably about 30 ng/ml of culture medium.
- the proliferaf ⁇ dn culture medium rurtnsr contains an effective amount of an insulin-like growth factor.
- the insulin ⁇ like growth factor is preferably insulin-like growth factor I and an effective amount of insulin-like growth factor I is from about 10 to about 100 ng/ml of culture medium and, more preferably about 40 ng/ml of culture medium.
- the proliferation culture medium can further contain transferrin, progesterone, putrescine, insulin and a selenite salt.
- An especially preferred proliferation medium is a 3:1 mixture of DMEM and F-12, supplemented in this manner.
- the serum in the proliferation medium is preferably normal horse serum. Serum is preferably present in a concentration of from about 1 volume percent to about 25 volumes percent, more preferably from about 2 to about 10 volumes percent and, even more preferably about 5 volumes percent.
- the cell concentration is between about 10 2 and 10* cells per mm 2 of culture vessel surface and, more preferably about 2 x 10 3 cells per mm 2 .
- the present invention provides a human fetal central nervous system progenitor cell produced by a process of the present invention.
- the present invention provides a process of preparing a differentiated, human central nervous system cell comprising the steps of:
- inducing differentiation is accomplished by dissociating progenitor cells from the cellular mass, plating the dissociated cells onto adherent culture dishes and culturing the dissociated cells in a differentiation culture medium.
- the differentiation medium contains serum such as fetal bovine serum and a minimal essential medium such as Dulbecco's MEM.
- a differentiated cell produced by a process of the present invention can be a glial cell or a neuron including, but not limited to, a cholinergic neuron, a peptidergic neuron, a GABAergic neuron, a glutamatergic neuron or a catecholaminergic neuron.
- Preferred embodiments for the process of producing a differentiated cell are the same as set forth above with regard to the process of preparing a progenitor cell.
- the present invention also provides a differentiated human central nervous system cell produced by a process of this invention.
- That differentiated cell can be a glial cell or a neuron.
- the present invention provides a screening assay for identifying substances that alter the function of a human central nervous system progenitor or differentiated cell, the process comprising the steps of: (a) establishing a culture of proliferating human central nervous system progenitor cells or differentiated cells; and (b) testing the ability of a substance to alter the function of those cells.
- progenitor or differentiated cells are established in accordance with the processes set forth above.
- testing is accomplished by exposing the cells to a substance suspected of altering function. Exposing is preferably accomplished by culturing the cells in a culture medium containing the substance suspected of altering function. In another embodiment, exposing is accomplished by transfecting the progenitor or differentiated cell with an expression vector that contains a polynucleotide at encodes the substance suspected of altering function, the expression vector driving expression of the substance in the cell.
- the present invention provides a composition for use in proliferating human fetal central nervous system progenitor cells comprising (a) a minimal essential medium; (b) serum: and (c) an effective amount of epidermal growth factor.
- the effective amount of epidermal growth factor is from about 1 ng/ml to about 100 ng/ml of medium, more preferably from about 10 to about 50 ng/ml of culture medium and, even more preferably about 30 ng/ml of culture medium.
- a composition of the present invention can further comprise an effective amount of an insulin-like growth factor such as insulin-like growth factor I.
- An effective amount of insulin-like growth factor is preferably from about 10 to about 200 ng/ml of culture medium and, more preferably about 40 ng/ml of culture medium.
- the composition can further comprise transferrin, progesterone, putrescine, insulin and a selenite salt. ⁇ . Human Fetal Central Nervous System Progenitor Cells
- the present invention provides a process of preparing a human fetal central nervous system progenitor cell. That process comprises the steps of: (a) culturing a population of cells from human fetal central nervous system tissue in a proliferation culture medium in a non-adherent culture dish containing serum and an effective amount of epidermal growth factor; and (b) maintaining the population of cells in the culture medium for a period of time sufficient for formation of a cellular mass that contains progenitor cells.
- a central nervous system “progenitor” cell means an omnipotent cell that is capable of asymmetric cell division and produces daughter cells capable of differentiation into neurons or glial cells.
- Central nervous system tissue is typically obtained from the developing central nervous system of fetuses available from elective abortion.
- Central nervous system tissue is dissociated from the fetus using standard dissociation techniques well known in the art.
- cells are physically dissociated from specific regions of the central nervous system by blunt dissection.
- cells are obtained by chemical means including treatment of tissue with enzymes such as trypsin, collagenase and the like.
- central nervous system means the brain and spinal cord or fetal tissue that gives rise to those tissues in the adult.
- Central nervous system cells once dissociated from tissue, are typically purified using standard procedures well known in the art. Exemplary purification procedures are centrifugation of cells suspended in a physiological medium and passage of suspended cells through filters (e.g., pipettes) of various pore size.
- Preferred physiological media include isotonic solutions of NaCl, balanced salt solutions and the like.
- a physiological medium is preferably calcium (Ca) and magnesium (Mg) free and can comprise enzymes such as trypsin and DNase to minimize clumping of cells. The existence of viable cells is confirmed by standard techniques such as ethidium bromide exclusion.
- a population of cells for use in a process of the present invention can be obtained from any specific region of the human fetal central nervous system. Selection of a particular region will determine to a large extent the particular nature of differentiated cells obtained from formed progenitor cells. Exemplary specific regions are ventral forebrain, cerebral cortex, cerebellum, midbrain and brainstem.
- Dissociated cells are suspended in a proliferation culture medium and plated onto a culture container having a non-adherent surface.
- a proliferation culture medium As used herein, the term "non-adherent" or its grammatical equivalent indicates a surface coating to which cells will not adhere.
- Non-adherent culture containers are well known in the art and are commercially available.
- a proliferation culture medium can be any minimal essential medium (MEM)known to support cell growth.
- a proliferation medium contains an isotonic level of balanced salts, nutrients such as amino acids, vitamins, and growth supporting factors such as transfe ⁇ in, progesterone, putrescine, insulin and selenite.
- Exemplary proliferation media are Dulbecco's Minimal Essential Medium (DMEM) and Ham's F-12.
- DMEM Dulbecco's Minimal Essential Medium
- F-12 Ham's F-12
- a proliferation medium is a mixture of DMEM and F-12 in a 3:1 ratio.
- Media for use in a process of the present invention can be made or purchased from commercial sources.
- a proliferation medium comprises an effective amount of epidermal growth factor (EGF).
- EGF epidermal growth factor
- an effective amount means that concentration of EGF that results in proliferation of progenitor cells. Means for determimng an effective amount are well known in the art. One skilled in the art can simply alter the concentration of EGF and determine the effects of such alteration on proliferation. An effective amount of EGF depends inter alia on the concentration of cells in the proliferation medium, the nutrient level of that medium and the absence or presence of other growth supporting factors in the medium.
- an effective amount of EGF is preferably from about 1 ng/ml of medium to about 100 ng/ml of medium. More preferably, under those conditions, an effective amount of EGF is from about 10 ng/ml of medium to about 50 ng/ml of medium and, even more preferably from about 20 ng/ml of medium to about 40 ng/ml of medium.
- the proliferation medium can further comprise an effective amount of an insulin-like growth factor (IGF).
- IGF insulin-like growth factor
- a preferred IGF is IGF-I.
- An effective amount of an IGF is determined in the same manner as set forth above with regard to EGF. Under the specific culture conditions set forth hereinafter in the examples, an effective amount of an IGF is from about 1 ng ml of medium to about 100 ⁇ g/ml of medium. Preferably, the effective amount of an IGF is from about 10 ng/ml of medium to about 100 ng/ml of medium and, more preferably about 40 ng/ml of medium.
- the concentration of cells in the proliferation medium is selected to maximize proliferation. That concentration depends, as is well known in the art, on the nature of the proliferation medium (e.g., level of nutrients). Means for determining a cell concentration are well known in the art.
- the concentration of cells is from about 10 2 to about 10 4 cells/mm 2 . More preferably, cell concentration is from about 10 2 to about 5 x 10 3 cells/mm 2 and, more preferably about 2 x 10 3 cells/mm 2 .
- the proliferation medium used to prepare proliferating human fetal central nervous system cells contains normal serum.
- Normal serum can be derived from bovine, equine, chicken and the like. Normal horse serum is preferred.
- the concentration of serum can range from about 1 percent by volume to about 25 percent by volume. Preferably, the concentration of serum is from about 2 percent by volume to about 10 percent by volume and, more preferably about 5 percent by volume.
- Cells are cultured in proliferation medium, under the conditions set forth above, for a period of time sufficient for formation of a cellular mass that contains progenitor cells capable of proliferation and differentiation.
- Culture conditions are those physiological conditions necessary for cell viability and include temperature, pH, osmolality and the like.
- the temperature is from about 30 ⁇ C to about 40°C, more preferably from about 35 ⁇ C to about 39 ⁇ C and, even more preferably about 37 ⁇ C.
- the pH value is preferably from about a valueof about 6 to a value of about 8, more preferably from a value of about 6.5 to a value of about 7.5. and, even more preferably about 7.4.
- Osmolality is preferably from about 250 mosmols/liter to about 320 mosmols/liter, more preferably from about 270 mosmols/liter to about 310 mosmols/liter and, even more preferably from about 280 mosmols/liter to about 300 mosmols/liter.
- Cells in culture are fed as needed by replacing the proliferation medium with fresh medium containing the specified growth factors and serum. Typically, feeding occurs every 3-4 days.
- Human fetal central nervous system cells cultured as described above, form cellular masses that contain progenitor cells. Those cellular masses are typically spherical in nature. The progenitor cells in those masses can be dissociated and further propagated (e.g., subcultured) to form further masses of proliferating cells. Using a process of the present invention, human fetal progenitor cells can be propagated for extended periods of time (see the Examples hereinafter showing prpagation for at least four months in culture). The propagation of progenitor cells from adult and fetal rodent central nervous system tissue has been reported (See, e.g.. PCT Publication WO 93/01275). As reported hereinafter in the examples, human fetal central nervous system progenitor cells could not be propagated using the compositions and process reported in that publication.
- the present invention also contemplates proliferating human fetal central nervous system progenitor cells prepared in accordance with a process of this invention. Those cells can be individual cells existing in a suspension culture or cells contained in cellular masses as set forth above. Thus, the present invention provides a culture of human fetal central nervous system progenitors cells capable of propagation in culture and differentiation.
- a progenitor cell contemplated by the present invention can be derived from any specific region of human fetal central nervous system as set forth above.
- a human fetal central nervous system progenitor cell of the present invention can be induced to differentiate into neural and glial cells.
- the present invention contemplates a process of preparing such differentiated cells comprising inducing differentiation of progemtor cells of the present invention.
- a process of preparing a human central nervous system differentiated cell comprises the steps of:
- the proliferation medium further comprises IGF and, more preferably IGF-1.
- IGF IGF and, more preferably IGF-1.
- Preferred concentrations of IGF are the same as set forth above.
- Differentiation can be induced using any means well known in the art
- differentiation is induced by dissociating progenitor cells from the cellular mass, plating the dissociated cells onto an adherent culture dish and culturing the dissociated mass in a differentiation culture medium.
- Progenitor cells are typically dissociated from the cellular mass using trituration with a pipette, usually after prior incubation with proteolytic enzymes.
- Culture containers having an adherent coating are well known in the art.
- adherent coatings include polyamines such as poly-L-lysine and poly-L-ornithine and extracellular matrix substances such as collagen, laminin and fibronectin. Culture containers having such coatings are commercially available.
- the differentiation medium is any minimal essential medium that supports growth and differentiation. Exemplary and preferred such media are the same as set forth above. A preferred differentiation medium is
- the differentiation medium can further comprise serum and, preferably fetal serum such as bovine fetal serum.
- the concentration of serum can range from about 1 percent by volume to about 25 percent by volume, preferably from about 5 percent by volume to about 15 percent by volume and, more preferably about 10 percent by volume.
- Growth factors may be present in the differentiation medium.
- a human central nervous system differentiated cell prepared by a process of the present invention can be a neuron or a glial cell. More than one type of neuron can be prepared by a process of the present invention. The particular neuron type prepared depends inter alia upon the specific region of the central nervous system from which the progenitor cells are derived. Neuron types preparable by a process of the present invention include, but are not limited to, cholinergic neurons, peptidergic neurons, GABAergic neurons, glutamatergic neurons and catecholaminergic neurons.
- neuron prepared is determined using standard procedures well known in the art.
- differentiated cells are screened and identified using immunohistochemical techniques employing antibodies for known cell markers.
- immunohistochemical techniques is also used to identify differentiated glial cells.
- Antibodies against specific neural and glial cell markers are well known in the art.
- Exemplary cell markers are neuron-specific enolase (NSE), neurofilament
- NF glial fibrillary associated protein
- GalC galactocerebroside
- acetylcholine ACh
- dopamine DA
- E epinephrine
- NE norepinephrine
- H histamine
- SP substance P
- SP human nerve growth factor receptor
- NTF-R choline acetyltransferase
- Enk enkephalin
- GAD glutamic acid decarboxylase
- TH tyrosine hydroxylase
- ADC dynorphin and aromatic amino acid decarboxylase
- the differentiation of human fetal central nervous system cells is regulated. Regulation is accomplished by adding defined growth factors and/or conditioned media to either or both of the proliferation and differentiation medium. Those growth factors can be used to direct differentiation toward specific cell types. Regulating the differentiation of specific cell types can also be accomplished as is well known in the art by
- the present invention also contemplates differentiated human central nervous system cells as provided by a process of this invention. Those cells can exist as isolated and purified cells or as a culture of such cells. Differentiated neuronal and glial cells are contemplated by this invention.
- Human central nervous system progenitor and differentiated cells of the present invention can be used in a variety of ways including screening assays for the identification of substances that affect the function of those cells and for ex vivo transplantation.
- the present invention contemplates a process of screening substances for their ability to interact with a progenitor or differentiated human central nervous system cell of the present invention.
- Such a screening assay comprises the steps of providing a progenitor or differentiated cell of the present invention and testing the ability of selected substances to affect the function of that cell.
- providing a progenitor or differentiated cell is accomplished using a process set forth above.
- Testing the ability of a selected substance to affect cell function is accomplished by exposing a culture of a progenitor or differentiated cells to a candidate substance suspected of affecting cell function, maintaining the cell under biological conditions and detecting the functional effects of that candidate substance.
- screening assays are provided for the testing of candidate substances such as inducers of differentiation, inhibitors of differentiation, drugs that are agonists or antagonists of cell receptors or membrane channels (e.g., Na channel, K channel, Ca channel, neurotransmitter receptors), toxins, drugs that affect membrane permeability to selective ions (e.g., Na, K, Cl, Ca), second messengers or gene expression and the like.
- a candidate substance is a substance which potentially can interact with or modulate, by binding or other intramolecular interaction, the metabolic or electrical properties of a progenitor or differentiated cell.
- Cells of the present invention are useful because of the difficulty in obtaining sufficient human central nervous system tissue for study.
- a screening assay of the present invention has several advantages over currently available assays.
- a major advantage is the availability of large amounts of uniform, nontransformed human central nervous systems cells.
- the investigator may now control the type of neuron or cell that is utilized in a screening assay. Specific neuronal cell types can be prepared expressed and their interaction with a substance can be identified.
- Other advantages include the availability of isolated neuron types previously difficult to obtain in tissue samples, and the obviation of finding a continuous supply of human material, particularly fetal material.
- a screening assay provides a cell under conditions suitable for the testing of a candidate substance. These conditions include but are not limited to pH, temperature, tonicity, the presence of relevant co-factors and the like.
- the present invention provides culture conditions and compositions suitable for the prolonged culturing of both progemtor and differentiated human central nervous system cells.
- a typical screening assay for identifying candidate substances cells are placed into a suitable culture medium (proliferation or differentiation).
- Candidate substances are added to the medium in convenient concentrations and the interaction between the candidate substance and the cell is momtored. By comparing reactions which are carried out in the presence or absence of the candidate substance, one can then obtain information regarding the effect of candidate/receptor interaction on the cell's function.
- this aspect of the present invention provides those of skill in the art with methodology that allows for the identification of candidate substances having the ability to modify the function of a human central nervous system progemtor or differentiated cell in one or more manners.
- a progenitor or differentiated cell can be exposed to that substance by transfecting the cell with an expression vector that contains a polynucleotide that encodes that polypeptide.
- the expression vector drives expression of the polypeptide in the progenitor or differentiated cell.
- Means of transfecting central nervous system cells are well known in the art and include techniques such as calcium-phosphate- or DEAE-dextran-mediated transfection, protoplast fusion, electroporation, liposome mediated transfection, direct microinjection and adenovirus infection.
- transfection mediated by either calcium phosphate or DEAE-dextran The most widely used method is transfection mediated by either calcium phosphate or DEAE-dextran. Although the mechamsm remains obscure, it is believed that the transfected DNA enters the cytoplasm of the cell by endocytosis and is transported to the nucleus. Depending on the cell type, up to 90% of a population of cultured cells can be transfected at any one time. Because of its high efficiency, transfection mediated by calcium phosphate or DEAE-dextran is the method of choice for experiments that require transient expression of the foreign DNA in large numbers of cells. Calcium phosphate-mediated transfection is also used to establish cell lines that integrate copies of the foreign DNA, which are usually arranged in head-to-tail tandem arrays into the host cell genome.
- protoplasts Ofettveinrom 1 Dacte ⁇ a carrying high numbers of copies of a plasmid of interest are mixed directly with cultured mammalian cells. After fusion of the cell membranes (usually with polyethylene glycol), the contents of the bacteria are delivered into the cytoplasm of the mammalian cells and the plasmid DNA is transported to the nucleus.
- Protoplast fusion is not as efficient as transfection for many of the cell lines that are commonly used for transient expression assays, but it is useful for cell lines in which endocytosis of DNA occurs inefficiently. Protoplast fusion frequently yields multiple copies of the plasmid DNA tandemly integrated into the host chromosome.
- Electroporation can be extremely efficient and can be used both for transient expression of cloned genes and for establishment of cell lines that carry integrated copies of the gene of interest. Electroporation, in contrast to calcium phosphate-mediated transfection and protoplast fusion, frequently gives rise to cell lines that carry one, or at most a few, integrated copies of the foreign DNA.
- Liposome transfection involves encapsulation of DNA and RNA within liposomes, followed by fusion of the liposomes with the cell membrane. The mechanism of how DNA is delivered into the cell is unclear but transfection efficiencies can be as high as 90%.
- Direct microinjection of a DNA molecule into nuclei has the advantage of not exposing DNA to cellular components such as low-pH endosomes. Microinjection is therefore used primarily as a method to establish lines of cells that carry integrated copies of the DNA of interest.
- S ⁇ SSTiTUTE SHEET (RULE 26)
- adenovirus vector-mediated cell transfection has been reported for various cells including cells of the central nervous system.
- Expression vectors that drive expression of a polypeptide typically include (if necessary) an origin of replication, a promoter, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences. Promoters specific to the cell being studied are preferred. Thus, where a neuron is transfected, a preferred promoter is a neurofilament or neuron-specific enolase promoter. Other promoters that have particular utility in neural cells are promoters associated with the production of neurotransmitters such as ACh, E, NE, 5-HT and doparnine.
- control functions on the expression vectors are often derived from viral material.
- promoters are derived from polyoma, Adenovirus 2, Cytomegalovirus and most frequently Simian Virus 40 (SV40).
- SV40 Simian Virus 40
- the early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication.
- An origin of replication can be provided with by construction of the vector to include an exogenous origin, such as can be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV, CMV) source, or can be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
- an exogenous origin such as can be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV, CMV) source, or can be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
- a transfected progenitor or differentiated human central nervous system cell can also be used in a screening assay to test for candidate substances that affect cell function.
- such a cell can be used for propagating human neurotropic viruses or other fastidious pathogens, for research, development of vaccines, or other purposes.
- Human progenitor and differentiated cells of the central nervous system of the present invention provide a source of human cells for use in ex vivo transplantation into the human brain. Ex vivo transplantation is becoming a treatment of choice for certain pathological disorders of the central nervous system.
- Alzheimer's Disease such as Alzheimer's Disease, Huntington's Chorea and Parkinson's Disease have been linked to the degeneration of neurons in specific locations in the brain and the inability of the brain region to synthesize and release neurotransmitters and other substances vital to neuron function.
- drugs and other pharmacological agents has limited utility for treatment of central nervous system pathologies.
- Drugs administered via typical parenteral routes of administration have difficulty in reaching target tissues in the brain because of transport problems across the blood-brain barrier. Administration directly into the brain or spinal cord gives rise to potential infection in those tissues. Further, tolerance to drugs is often associated with long-term use of those drugs. By way of example, despite partial restoration of dopaminergic activity seen in Parkinson's patients treated with L-dopa, those patients often become tolerant to the effects of L- dopa, and thus require increasing dosages to maintain the beneficial effects of that drug.
- Neurological tissue grafting of tissue into the central nervous system has been used to overcome some of the problems associated with drug therapy.
- ex vivo treatment is used to replace the source of a particular substance where the intrinsic source of that substance has been destroyed as a result of dysfunction.
- Parkinson's Disease is associated with a loss of doparnine producing cells in the brain.
- the transplantation of cells that produce doparnine can be used to partially restore brain function.
- ex vivo treatment often involves the use of cells and tissue from other sources.
- tissues and cells are adrenal medulla (adrenal chromaffin cells), neurons from the adult peripheral nervous system (PNS), chromaffin cells and fetal ventral mesencephalon from non-human species and immortalized cell lines derived either by transformation of normal cells or by culturing cells with altered growth characteristics.
- PNS peripheral nervous system
- chromaffin cells and fetal ventral mesencephalon from non-human species and immortalized cell lines derived either by transformation of normal cells or by culturing cells with altered growth characteristics.
- non-human cells give rise to an immune response.
- non-neural cells compromises the ability of the grafted cells to functionally integrate with the CNS.
- transformed cells may form tumors in the patient's brain.
- the present invention provides such a reliable source of human fetal central nervous system tissue or cells.
- the present invention therefore provides a process of ex vivo treatment of human central nervous system disorders comprising administering to patients in need of such treatment, a human fetal central nervous system progenitor or differentiated cell of the present invention.
- Human fetal progenitor cells or differentiated cells of the present invention can also, in combination with routine immunosuppressive medication, be administered to any animal with abnormal neurological or neurodegenerative symptoms obtained in any manner, including those obtained as a result of chemical or electrolytic lesions, as a result of experimental aspiration of neural areas, or as a result of aging processes.
- Cells are delivered throughout any affected neural area. Cells are administered to a particular region using any method which maintains the integrity of surrounding areas of the brain, preferably by injection cannula.
- cells to use in transplantation depends upon the desired purpose of the treatment. Where, for example, it is desirable to restore levels of a particular substance (e.g., a neurotransmitter such as doparnine) to a region of the brain, cells that produce that substance are selected. Means for identifying particular cell types are set forth hereinbefore.
- a particular substance e.g., a neurotransmitter such as doparnine
- cells administered to the particular region of the brain form neuronal or synaptic connections with neighboring neurons, and maintain contact with glial cells which may form myelin sheaths around the neuron's axon.
- transplanted tissue survival of the transplanted tissue is determined using standard non- invasive procedures well known in the art. Such procedures include computerized axial tomography (CAT or CT scan), nuclear magnetic resonance or magnetic resonance imaging (NMR or MRI) and positron emission tomography (PET) scans. Functional integration of the cells into the host's neural network is assessed by examining the effectiveness of grafts on restoring various functions. In addition to restoring lost function (e.g., neurotransmitter production), cells of the present invention can be used to deliver drugs or other substances to specific regions of the central nervous system.
- CAT or CT scan computerized axial tomography
- NMR or MRI nuclear magnetic resonance or magnetic resonance imaging
- PET positron emission tomography
- a progenitor or differentiated cell is transfected with an expression vector containing a polynucleotide that encodes that substance, the expression vector driving expression of the substance in the transfected cell.
- Means for transfecting cells are set forth hereinbefore. Cells expressing the desired substance are transplanted to a desired location in the brain.
- EXAMPLE 1 Isolation of Human Fetal CNS Cells Human fetal brain tissue was obtained from routine therapeutic abortions performed at the Victoria General Hospital in Suite, Nova Scotia, with informed consent and approval of appropriate institutional ethical review boards. Evacuated tissue fragments from 6-8 week post-conception fetuses, as staged according to the developmental atlas of England (1983), were collected directly into sterile ice-cold isotonic saline with heparin (10 ⁇ g/ml).
- Ventral forebrain was dissected under stereomicroscopic observation in a laminar flow containment hood, and transferred to a solution of 0.05% (w/v) trypsin (Type XTJJ, Sigma) in calcium- and magnesium-free Hank's Balanced Salt Solution (CMF-HBSS) for 20 minutes at 37 ⁇ C.
- CMF-HBSS Hank's Balanced Salt Solution
- Progenitor cell culture medium was composed of a 3:1 mixture of Dulbecco's Minimum Essential Medium (DMEM:Gibco) and Ham's F-12 (Gibco), with 5% (v/v) horse serum (Gibco), insulin (Sigma, 10 ⁇ g/ml), transferrin (Sigma, 200 ⁇ g/ml, progesterone (Sigma, 40 mM), putrescine (Sigma, 200 ⁇ M) and sodium selenite (Sigma, 60 nM).
- DMEM Dulbecco's Minimum Essential Medium
- Gibco Ham's F-12
- PCM-E EGF (Upstate Biochemicals, 20ng/ml)
- PCM-EI EGF plus IGF-I (Upstate Biochemicals, lOOng/ml)
- PCM-EI EGF plus IGF-I
- Immunohistochemical staining revealed nestin-immunoreactive cells within the cellular masses when these masses were plated, undissociated, directly onto poly-L-lysine-coated plates for 48 hours. The masses attached loosely to the plate during this time period via small numbers of processes. After dissociating and replating the cells of these masses, 'secondary' cell masses formed; growth of secondary cells masses was less rapid than that of primary cell masses. After a further 30-60 DIV, secondary masses were similarly dissociated to produce 'tertiary' masses of proliferating cells. Such passage could be repeated at least 2 times.
- spherical proliferating cell masses were dissociated as above, and the resulting cell suspension plated onto poly-L- lysine (Sigma)-coated dishes in DMEM with 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- spherical masses of proliferating cells were, while still in PCM, exposed to l ⁇ g/ml bromodeoxyuridine (BrdU; Sigma), which is incorporated into the nuclear DNA of proliferating cells, for 6, 12, 18, 24, 36, 48, 60 or 72 hours. Cell masses were then dissociated, and the resulting cell suspension plated onto poly-L-lysine-coated plates in DMEM with 10% FBS.
- Immunocytochemical staining was carried out as previously described, using well-characterized antibodies specific for BrdU (Amersham), neurofilament 200 (NF; Sigma), glial fibrillary associated protein (GFAP; Sigma and DAKO), choline acetyltransferase (ChAT; Chemcion), glutamic acid decarboxylase (GAD; Calbiochem), tyrosine hydroxylase (TH; Eugene Tech), substance P (Sub-P, Eugene Tech), the neuronal/glial lineage marker
- Dilutions of primary antibodies or TT in 0.1 M phosphate buffer containing 1 % normal serum were as follows: rabbit anti-GFAP (1:100), rabbit anti-NF (1:200), mouse anti-BrdU (neat), rabbit anti-ChAT (1:1000), rabbit anti-GAD (1:200), rabbit anti-TH (1:1000), rabbit anti-Sub-P (1:1000), mouse anti- A2B5 (1:100), rabbit anti-nestin-129 (1:2000), and FITC-TT (200 ⁇ g/ml).
- Tertiary cell masses collected at least 75 days after initial primary plating, were redissociated and plated as single cells onto poly-L-lysine coated tissue culture dishes. After 5 DIV, these cells were fixed and stained immunohistochemically to evaluate their cytochemical phenotype; cells immunoreactive for NF, ChAT, GFAP, Sub-P, TH, A2B5, GAD and TT were evident. When these cells were derived from cellular masses incubated with BrdU for 48 hours immediately prior to dissociation, cells of each cytochemically-identified group were found with BrdU-labelled nuclei.
- tertiary cell masses were incubated with BrdU for various periods immediately prior to dissociation and replating; plated cells were fixed and stained immunocytochemically to detect BrdU-labelled cells.
- the percentage of cells incorporating BrdU into their nucleus increased with increasing incubation times from 12 to 36 hours; with longer incubations, the proportion of labelled nuclei remained unchanged at approximately 80% of the total.
- the pH of the perfusate was adjusted to 7.25 using NaOH, and osmolarity was adjusted to 350 mOsm using sucrose.
- Drugs were diluted from concentrated stock solution into the same si at solution which, in the case of experiments involving N-methyl-D- aspartate (NMDA), was supplemented with glycine (10 ⁇ M) but lacked
- the patch pipettes were filled with a solution containing (in mM): CsF, 120; CsCl, 10; Hepes, 10; EGTA, 10; CaCl 2 , 0.5.
- the pH was adjusted to
- NMDA excitatory amino acid analogs NMDA, ⁇ -amino- 3-hydroxy-5-methyl-isoxazolepropionate (AMPA) and kainate in a manner qualitatively similar to that of rat cortical neurons.
- AMPA ⁇ -amino- 3-hydroxy-5-methyl-isoxazolepropionate
- kainate in a manner qualitatively similar to that of rat cortical neurons.
- EGF and IGF-I when added to a partially defined medium, permit the survival and continued proliferation in vitro of progenitor cells from the fetal human forebrain for at least 4 months.
- progenitor cells remain in an undifferentiated state, expressing nestin, until they are stimulated to differentiate.
- differentiated cells were induced by changing culture conditions to FBS-supplemented medium in culture dishes coated to promote attachment.
- a wide range of differentiated cells can in this way be produced, including neurons (as indicated by expression of neurofilament) of several neurochemical classes (catecholaminergic as indicated by TH, peptidergic as indicated by Sub-P, cholinergic as indicated by ChAT and inhibitory GABAergic as indicated by GAD expression) and astrocytes (as indicated by GFAP expression).
- These differentiated neurons can be maintained in vitro for at least 15 weeks when cultured on glial feeder layers, and display normal and medically-significant receptors by electrical recording criteria.
- AU these differentiated cell types derived from progenitor cells of forebrain origin are also present in the normal adult forebrain. EGF and IGF-I also permitted the formation of proliferating cell masses from human fetal ventral mesencephalic cells.
- progenitor cells were incubated with BrdU at a concentration that would be incorporated into the DNA but not affect proliferation. The cells were then induced to differentiate, and stained for both BrdU and particular neurochemical markers. Double-labelled cells, immunoreactive for BrdU and for ChAT, substance P, TH or GAD were observed, establishing that all of these cells could be produced by progenitor cells replicating in culture prior to terminal differentiation.
- Double-labelled astrocytes (immunoreactive both for BrdU and for
- Trophic factor support for the proliferation and differentiation of neuron cells has been demonstrated by others.
- the ability of EGF and IGF-I to support proliferation of these undifferentiated progenitor cells supports the possibility that these mitogenic growth factors play a role in normal development of the fetal human forebrain.
- IGF-I mRNA has been shown to be present in the human fetal CNS and similarly EGF receptors have been localized throughout the adult human brain.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un procédé de préparation de cellules souches ou différenciées du système nerveux central f÷tal humain prolifératives ainsi que des cellules préparées selon ce procédé. Les cellules souches prolifératives sont préparées par mise en culture de tissu du système nerveux central de f÷tus humain dans un conteneur de culture non adhérent contenant du sérum et un facteur de croissance épidermique. L'invention concerne également une méthode de criblage ainsi que des traitements ex vivo utilisant ces cellules.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33385/95A AU3338595A (en) | 1994-07-29 | 1995-07-31 | Propagation and inducible differentiation of human fetal central nervous system progenitor cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28292794A | 1994-07-29 | 1994-07-29 | |
US282,927 | 1994-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004368A1 true WO1996004368A1 (fr) | 1996-02-15 |
Family
ID=23083726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1995/000445 WO1996004368A1 (fr) | 1994-07-29 | 1995-07-31 | Propagation et differenciation inductible de cellules souches du systeme nerveux central f×tal humain |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3338595A (fr) |
WO (1) | WO1996004368A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2301114A (en) * | 1995-05-24 | 1996-11-27 | Bradley Michael John Stringer | Method for controlling differentiation of precursor cells |
WO2000050572A1 (fr) * | 1999-02-26 | 2000-08-31 | Stemcells, Inc. | Utilisation de collagenase dans la preparation de cultures de cellules embryonnaires neuronales |
WO2001030981A1 (fr) * | 1999-10-25 | 2001-05-03 | Ns Gene A/S | Cultures de cellules gfap?+ nestin+¿ se differenciant en neurones |
US6277820B1 (en) | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
WO2003095629A1 (fr) * | 2002-05-10 | 2003-11-20 | Bresagen Ltd | Production de cellules souches neurales |
US7459152B2 (en) | 2003-04-23 | 2008-12-02 | Rush University Medical Center | Erythropoietin administration to improve graft survival |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001275A1 (fr) * | 1991-07-08 | 1993-01-21 | Neurospheres Ltd. | NOUVELLES CELLULES SOUCHES REAGISSANT AU FACTEUR DE CROISSANCE ET POUVANT PROLIFERER $i(IN VITRO) |
WO1994009119A1 (fr) * | 1992-10-16 | 1994-04-28 | Neurospheres Ltd. | Remyelination effectue a l'aide de cellules souches neurales |
WO1994010292A1 (fr) * | 1992-10-28 | 1994-05-11 | Neurospheres Ltd. | Facteurs biologiques et cellules souches neurales |
-
1995
- 1995-07-31 AU AU33385/95A patent/AU3338595A/en not_active Abandoned
- 1995-07-31 WO PCT/CA1995/000445 patent/WO1996004368A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001275A1 (fr) * | 1991-07-08 | 1993-01-21 | Neurospheres Ltd. | NOUVELLES CELLULES SOUCHES REAGISSANT AU FACTEUR DE CROISSANCE ET POUVANT PROLIFERER $i(IN VITRO) |
WO1994009119A1 (fr) * | 1992-10-16 | 1994-04-28 | Neurospheres Ltd. | Remyelination effectue a l'aide de cellules souches neurales |
WO1994010292A1 (fr) * | 1992-10-28 | 1994-05-11 | Neurospheres Ltd. | Facteurs biologiques et cellules souches neurales |
Non-Patent Citations (2)
Title |
---|
REYNOLDS A. ET AL.: "Generation of Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous System", SCIENCE, vol. 255, 27 March 1992 (1992-03-27), LANCASTER, PA US, pages 1707 - 1710 * |
VON VISGER J R ET AL: "Differentiation and maturation of astrocytes derived from neuroepithelial progenitor cells in culture.", EXPERIMENTAL NEUROLOGY 128 (1). 1994. 34-40. * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2301114A (en) * | 1995-05-24 | 1996-11-27 | Bradley Michael John Stringer | Method for controlling differentiation of precursor cells |
US6277820B1 (en) | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
WO2000050572A1 (fr) * | 1999-02-26 | 2000-08-31 | Stemcells, Inc. | Utilisation de collagenase dans la preparation de cultures de cellules embryonnaires neuronales |
US7049141B1 (en) | 1999-02-26 | 2006-05-23 | Stemcells California, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
US6238922B1 (en) | 1999-02-26 | 2001-05-29 | Stemcells, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
EP1533367A1 (fr) * | 1999-02-26 | 2005-05-25 | StemCells, Inc. | Utilisation de collagénase pour la préparation des cellules souches neurales |
US6878543B1 (en) | 1999-10-25 | 2005-04-12 | Nsgene Sa | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
WO2001030981A1 (fr) * | 1999-10-25 | 2001-05-03 | Ns Gene A/S | Cultures de cellules gfap?+ nestin+¿ se differenciant en neurones |
US7303912B2 (en) | 1999-10-25 | 2007-12-04 | Nsgene A/S | Cultures of GFAP nestin cells that differentiate to neurons |
US7651853B2 (en) | 1999-10-25 | 2010-01-26 | Nsgene A/S | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
US8501467B2 (en) | 1999-10-25 | 2013-08-06 | Stemcells California, Inc. | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
WO2003095629A1 (fr) * | 2002-05-10 | 2003-11-20 | Bresagen Ltd | Production de cellules souches neurales |
US7459152B2 (en) | 2003-04-23 | 2008-12-02 | Rush University Medical Center | Erythropoietin administration to improve graft survival |
Also Published As
Publication number | Publication date |
---|---|
AU3338595A (en) | 1996-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hartikka et al. | Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth, and expression of transmitter-specific enzymes | |
Moriarty et al. | A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells | |
AU665012B2 (en) | Novel growth factor-responsive progenitor cells which can be proliferated (in vitro) | |
US8501467B2 (en) | Cultures of GFAP+ nestin+ cells that differentiate to neurons | |
Chalmers-Redman et al. | In vitro propagation and inducible differentiation of multipotential progenitor cells from human fetal brain | |
Arias‐Carrion et al. | Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions | |
Avellana‐Adalid et al. | Expansion of rat oligodendrocyte progenitors into proliferative “oligospheres” that retain differentiation potential | |
ES2194016T5 (es) | Factores biologicos y celulas germinales neurales. | |
Rubio et al. | BDNF gene transfer to the mammalian brain using CNS-derived neural precursors | |
O'malley et al. | Local support cells promote survival of substantia nigra dopaminergic neurons in culture | |
NO321000B1 (no) | Fremgangsmate for indusering av ekspresjon av tyrosinhydroksylase i nerveceller fra pattedyr-CNS, unntatt humane embryonale stanceller og en fremgangsmate for screening av et medikaments effekt pa dopaminerge celler, samt cellekultur og anvendelse av slike celler for behandling av neurologiske forstyrrelser. | |
US20090136456A1 (en) | Methods of treating neurodegenerative disorders | |
WO1996004368A1 (fr) | Propagation et differenciation inductible de cellules souches du systeme nerveux central f×tal humain | |
Mason et al. | Isolation and characterization of neonatal Schwann cells from cryopreserved rat sciatic nerves | |
Pal-Ghosh et al. | Mechanisms Regulating Mitochondrial Transfer in Human Corneal Epithelial Cells | |
WO2004013315A1 (fr) | Procede de preparation, de purification et de differenciation de neurospheres issues de cellules souches de mammiferes | |
Pham Truong | Functional analysis of axon guidance programs in developmental photoreceptor connectivity | |
EP1565550A1 (fr) | Procede d'isolation de cellules souches pluripotentes | |
US20040115807A1 (en) | O-2a progenitors multipotent cells from neurohypophysis | |
MXPA97003493A (en) | In vitro induction of dopaminergi cells | |
Yuliya | Neural stem cells from embryonic brain of mice and neural cell adhesion molecule L1 and projection aberrations to the hippocampus in NCAM deficient mice (Mus musculus L., 1758) | |
Tereshchenko | Neural stem cells from embryonic brain of mice and neural cell adhesion molecule L1 and projection aberrations to the hippocampus in NCAM deficient mice (Mus musculus L., 1758) | |
Colombo et al. | Forebrain and midbrain astrocytes promote neuritogenesis in cultured chromaffin cells | |
Loo | Nonsenescent serum-free mouse proastroblasts: Extended culture, growth responses in vitro, and application to the culture of human embryonic astrocytes | |
Ardelt | Murine striatal development in vivo and in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |